NiCE Actimize X-Sight AI Enterprise Platform Increases Modernization of KeyBank's Financial Crime Operations
KeyBank's objectives in its modernization were to tackle a variety of operational challenges, while enhancing overall efficiency. Now fully live with fraud and anti-money laundering capabilities, the advanced SaaS platform is designed to reduce disruptions caused by system downtime or performance issues so that KeyBank can now more swiftly resolve issues and achieve enhanced overall system reliability and a smoother, more dependable banking experience.
With built-in agility derived from NiCE Actimize's Integrated Fraud Management (IFM) system, KeyBank can now more quickly adapt workflows and implement new compliance measures in response to changing regulations and new types of fraud. KeyBank incorporated NiCE Actimize's ActOne case management capabilities into the modernized approach and additionally updated its platform with the addition of X-Sight Enterprise for Anti-Money Laundering, including CDD capabilities.
'KeyBank sought to future-proof its operations, and NiCE Actimize's advanced X-Sight AI Enterprise platform provided a seamless path,' said Amy Brady, Chief Information Officer, KeyBank. ' We were challenged by increased costs associated with manual system upgrades and patches. By replacing our previous solutions, we have ensured consistent performance and minimized system downtime, allowing the organization to respond more effectively to evolving regulatory changes.'
Explained Craig Costigan, CEO, NiCE Actimize, ' The X-Sight AI platform helps firms simplify the complexities of managing multiple deployments, providing a comprehensive view of transactions and potential risks. One significant benefit is that the platform ensures banks can utilize the most advanced capabilities without the delay of manual updates. This enables the adoption of future innovations such as advanced analytics which enhance fraud detection and regulatory compliance.'
In addition to being a NiCE Actimize customer, KeyBank also leverages NiCE's AI-powered workforce augmentation capabilities to boost operational efficiency and enhance both employee and customer experiences. By introducing forecasting and scheduling with greater automation and precision, leadership improved reporting accuracy and hit service level goals all year. The standout achievement: hundreds of 'man-hours' saved during the busiest time of the year through NiCE's self-service PTO bidding, freeing resources to optimize service, and providing employees with more flexibility.
About KeyCorp
In 2025, KeyCorp celebrates its bicentennial, marking 200 years of service to clients and communities from Maine to Alaska. To learn more, visit KeyBank Heritage Center. Headquartered in Cleveland, Ohio, Key is one of the nation's largest bank-based financial services companies, with assets of approximately $189 billion at March 31, 2025.
Key provides deposit, lending, cash management, and investment services to individuals and businesses in 15 states under the name KeyBank National Association through a network of approximately 1,000 branches and approximately 1,200 ATMs. Key also provides a broad range of sophisticated corporate and investment banking products, such as merger and acquisition advice, public and private debt and equity, syndications and derivatives to middle market companies in selected industries throughout the United States under the KeyBanc Capital Markets trade name. For more information, visit https://www.key.com/. KeyBank Member FDIC.
About NiCE Actimize
As a global leader in artificial intelligence, platform services, and cloud solutions, NiCE Actimize excels in preventing fraud, detecting financial crime, and supporting regulatory compliance. Over 1,000 organizations across more than 70 countries trust NiCE Actimize to protect their institutions and safeguard assets throughout the entire customer lifecycle. With NiCE Actimize, customers gain deeper insights and mitigate risks. Learn more at www.niceactimize.com.
About NiCE
NiCE (NASDAQ: NICE) is transforming the world with AI that puts people first. Our purpose-built AI-powered platforms automate engagements into proactive, safe, intelligent actions, empowering individuals and organizations to innovate and act, from interaction to resolution. Trusted by organizations throughout 150+ countries worldwide, NiCE's platforms are widely adopted across industries connecting people, systems, and workflows to work smarter at scale, elevating performance across the organization, delivering proven measurable outcomes.
Trademark Note: NiCE and the NiCE logo are trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE's marks, please see: www.nice.com/nice-trademarks.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Costigan, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the 'Company'). In some cases, such forward-looking statements can be identified by terms such as 'believe,' 'expect,' 'seek,' 'may,' 'will,' 'intend,' 'should,' 'project,' 'anticipate,' 'plan,' 'estimate,' or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in general economic and business conditions; competition; successful execution of the Company's growth strategy; success and growth of the Company's cloud Software-as-a-Service business; rapid changes in technology and market requirements; the implementation of AI capabilities in certain products and services, decline in demand for the Company's products; inability to timely develop and introduce new technologies, products and applications; difficulties in making additional acquisitions or difficulties or effectively integrating acquired operations; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company's dependency on third-party cloud computing platform providers, hosting facilities and service partners; cyber security attacks or other security incidents; privacy concerns; changes in currency exchange rates and interest rates, the effects of additional tax liabilities resulting from our global operations, the effect of unexpected events or geo-political conditions, including those arising from political instability or armed conflict that may disrupt our business and the global economy; our ability to recruit and retain qualified personnel; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the 'SEC'). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company's reports filed from time to time with the SEC, including the Company's Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 928,596 shares of common stock of the Company originally issued in December 2024 and January 2025, having exercise prices between $2.00 and $3.00 per share. Warrants to purchase 100,000 shares of common stock at the existing exercise price of $2.00 per share will be exercised at their existing exercise price of $2.00 per share and warrants to purchase 828,596 shares of common stock will be exercised at a reduced exercise price of $2.485 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statement on Form S-1 (No. 333-284381). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.5 million, prior to deducting placement agent fees and offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional $232,149 in the aggregate, which are included in the gross proceeds to the Company), the exercising holders will receive new unregistered warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"). The new warrants will be exercisable for an aggregate of up to 1,857,192 shares of common stock, at an exercise price of $2.485 per share and will be immediately exercisable upon issuance and (i) will have a term of twenty-four months with respect to new warrants to purchase up to 1,538,596 shares of common stock and (ii) will have a term of five years with respect to new warrants to purchase up to 318,596 shares of common stock, in each case, following the effective date of the resale registration statement registering the shares of common stock issuable upon exercise of the new warrants. The offering is expected to close on or about July 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes. The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the 1933 Act and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. For additional information, visit the Company's website, Forward-Looking Statements completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law. Contact:Phio Pharmaceuticals Phillips: jphillips@ Affairs To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Saia beginning to shake off growing pains
The 2025 first quarter could be the operational nadir for less-than-truckload carrier Saia. The company reported sequential improvement in second-quarter financial results on Friday as it appears to have a better handle on costs following a significant expansion to its terminal footprint. Saia (NASDAQ: SAIA) had 21 more facilities in the second quarter than it did a year ago. The added costs weighed on results as the carrier is still in the process of matching head count to volumes. The Johns Creek, Georgia-based company reported second-quarter earnings per share of $2.67 before the market opened on Friday. The result was 28 cents ahead of the consensus estimate and 81 cents better than the first quarter. However, on a year-over-year comparison, EPS was down $1.16, with the bulk of the deterioration tied to startup costs at new locations. Higher interest expense (debt used to fund the terminal purchases pushed net debt $125 million higher y/y) and a slightly higher tax rate combined for a 10-drag on the quarter. Tonnage comps get tougher after 22-month run Saia reported second-quarter revenue of $817 million, a less than 1% y/y decline but $9 million ahead of analysts' expectations. Tonnage increased 1% y/y, the result of a 3% decline shipments, which was offset by a 4% increase in weight per shipment. On a y/y comparison, tonnage was 4.4% higher in April, down 0.4% in May and off 0.8% in June. Tonnage is flat y/y so far in July. The y/y comparisons are now more formidable for Saia following 22 consecutive months of gains, which began just ahead of Yellow Corp.'s July 2023 collapse. Saia faces positive y/y comps ranging from mid-single- to low-double-digits for the rest of the year. The remaining third-quarter comps include y/y increases of 8% and 10% in August and September, respectively. The carrier noted an unfavorable sequential mix shift toward lighter, retail freight at national accounts. (Weight per shipment was down 2% from the first quarter.) Also, it had less freight originating in Los Angeles, which pushed length of haul 1% lower sequentially. Revenue per hundredweight, or yield, was down 2% y/y (1% lower excluding fuel surcharges). The y/y increase in shipment weights was a drag on the yield metric and only partially offset by a 1% y/y increase in length of haul. The carrier was also up against a plus-9% yield comp from a year ago. Contacts renewed 5.1% higher on average in the quarter, a step down from a 6.1% average in the first quarter. Contract renewals, too, are comping mid- to high-single-digit increases from a year ago. Operating ratio recovers from post-Covid-worst Q1/25 Saia reported a second-quarter operating ratio (inverse of operating margin) of 87.8%, which was 450 basis points worse y/y, but 330 bps better than the first quarter (the carrier's worst operating performance since the pandemic). The result was also 120 bps better than management's guidance. Cost per shipment was up 7.7% but revenue per shipment increased just 1.8%, a 590-bp negative spread. Cost per shipment was down 4% from the first quarter. Terminals opened less than three years operated at a mid-90s OR during the second quarter, which was an improvement from breakeven results in the first quarter. Most of the newer locations reported higher efficiency metrics. The new locations have also helped Saia reduce the number of shipment touches across the network. Salaries, wages and benefits expenses were 260 bps higher y/y as a percentage of revenue. The company implemented an annual wages-and-benefits increase of 4.1% in July 2024 but hasn't decided if an increase is in store for 2025. Head count was reduced 4.2% from March to June, which should begin to take some pressure off the expense line. Depreciation and amortization expense was up 130 bps y/y due to recent terminal investments. Purchased transportation expense declined 40 bps y/y. The company normally sees 100 to 200 bps of OR degradation from the second to third quarter. However, it hopes recent cost actions will allow it to minimize the degradation to just 100 bps this year. The OR guidance could be negatively impacted by roughly 75 bps if it decides to implement an annual compensation increase similar to last year. The loose guide implies an 88.8% OR in the third quarter, which would be 370 bps worse y/y. The company's long-term OR goal remains at sub-80%. In aggregate, Saia has inked deals to buy 31 terminals from defunct Yellow (OTC: YELLQ). Saia now operates a full-scale, national network of 213 terminals. Shares of Saia were up 5.6% at 2:46 p.m. EDT on Friday compared to the S&P 500, which was up 0.5%. More FreightWaves articles by Todd Maiden: Heartland Express books another loss in Q2 Knight-Swift's belt tightening offsets soft demand FedEx Freight gives shippers 'more time' to adjust to new LTL class rules The post Saia beginning to shake off growing pains appeared first on FreightWaves. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
BioSig Technologies and Streamex: Pioneering Real-World Asset Tokenization in the U.S. Market
LOS ANGELES, CA, NEW YORK & VANCOUVER, BC, USA & CANADA, July 25th, 2025, ChainwireIn a significant move poised to transform the landscape of digital asset trading, BioSig Technologies, Inc. (NASDAQ: BSGM) has merged with Streamex Exchange Corporation, a private entity focused on the tokenization of real-world assets (RWAs), particularly in the commodities sector. This strategic merger not only diversifies BioSig's offerings but also positions the combined company to lead the emerging market of regulated RWA tokenization in the United States. The company is currently awaiting the official name change on NASDAQ that will fully integrate them into their new vision. Henry McPhie: A Visionary Leader At the helm of this transformative journey is Henry McPhie, Co-Founder and Chief Executive Officer of Streamex. A seasoned entrepreneur and technologist, McPhie has a robust background in building innovative companies at the intersection of blockchain and finance. Before leading Streamex, he founded Lynx Web3 Solutions, which provided critical infrastructure for early-stage Web3 projects. Notably, he also launched FatCats Capital, a Solana-based NFT initiative that gained quick traction, becoming the third-largest NFT project globally at its time of launch. His engineering degree from McGill University complements his entrepreneurial ventures, equipping him with both technical expertise and a visionary approach. With a mission to revolutionize real-world asset tokenization, McPhie leads Streamex in integrating blockchain solutions to bring commodities on-chain, thereby enhancing market access and liquidity for 500 million new investors across diverse sectors. Streamex's Core Offerings Streamex is committed to developing compliant primary issuance and decentralized exchange infrastructure aimed at modernizing commodity markets. Some key offerings include: Access: Connecting over 500 million new investors to a market with $3 trillion in liquidity. Diversification: Providing access to a variety of private placements in traditional capital markets. Innovation: Creating and owning individualized royalties and streaming contracts through tokenization. Legal Framework: Collaborating with regulators to ensure a safe and stable investment environment. Security: Utilizing automation and blockchain technology for secure financing documentation. Strategic Share Exchange Agreement BioSig and Streamex recently completed a definitive share exchange agreement, making Streamex a wholly owned subsidiary of BioSig. As part of this agreement, Streamex's shareholders will receive a substantial share allocation in BioSig, converting the company into a pioneer in the blockchain space with plans to enhance the tokenization of physical assets such as gold and commodities. The merger's completion marks a critical step toward tapping into the approximately $142 trillion global commodities market, with a focus on accelerating the use of blockchain technology in commodity finance. Acquisition of a Regulated Broker-Dealer Adding to this momentum, BioSig recently engaged Compliance Exchange Group (CXG) to assist in acquiring a FINRA and SEC-registered broker-dealer. This acquisition aims to position Streamex as one of the first publicly traded, fully regulated RWA tokenization companies in the U.S. The broker-dealer's regulatory framework will allow Streamex to issue and trade tokenized assets under federal securities laws, expanding its market presence and providing institutional and retail investors access to gold-backed digital investment opportunities. With the global gold market valued at $22 trillion, this move is anticipated to bridge traditional finance and blockchain, offering simple, compliant access to gold investments through digital tokens. Market Resilience and Promising Forecasts The merger and acquisitions have already positively impacted BioSig's stock, which surged by 24.4% following the announcement of the share exchange. As BioSig transitions from a traditional medtech company to a multi-faceted player in the blockchain and digital asset arena, analysts predict a substantial increase in company earnings, with expectations of a 73.3% rise in 2025. Streamex is committed to holding significant amounts of physical gold, securely stored through top-tier bullion banks. These holdings will denominate the company's balance sheet in gold, promoting a recurring revenue model aligned with global trends in commodity finance. As BioSig Technologies and Streamex Exchange Corporation forge ahead together, they are set to revolutionize the way investors access real-world assets through blockchain technology. Under Henry McPhie's leadership, their commitment to compliance, innovation, and market expansion places them on the path to redefine traditional finance, bringing unprecedented opportunities in the burgeoning world of RWA tokenization. With their ambitious vision for the future and an integrated platform poised to lead the marketplace, the combined company is well-positioned to become a major player in the evolution of commodity markets, while they await the official name change on NASDAQ that solidifies their new identity. About Streamex Exchange Corporation Streamex is a gold treasury and infrastructure company building the foundation for on-chain commodity markets. With a focus on real-world asset (RWA) tokenization, Streamex is developing a vertically integrated platform that combines token issuance, trading infrastructure, and physical gold holdings positioning the Company to become one of Nasdaq's largest public holders of gold bullion. This strategic approach aligns with Streamex's mission to reshape global finance by bringing the approximately $142 trillion global commodities market on chain. By merging the security and trust of physical gold with the efficiency and transparency of blockchain, Streamex is creating scalable financial infrastructure for a new era of digital commodities. The Company plans to hold significant quantities of physical gold, securely vaulted through a top-tier bullion bank. Streamex will denominate the majority of its balance sheet in vaulted gold rather than fiat currency, supporting a long-term, value-based financial model. Combined with Streamex's Solana-based blockchain infrastructure, this strategy enables a recurring revenue model that supports the issuance of gold-backed digital assets. Streamex is a wholly owned subsidiary of BioSig Technologies, Inc. For more information on Streamex: PellPhoenix Media Permalink | © Copyright 2025 All rights reserved
